On January 5, 2021 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that Dr. Amit Kumar, Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021 (Press release, Anixa Biosciences, JAN 5, 2021, View Source [SID1234573473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Kumar will provide an overview of Anixa’s business and highlight recent corporate achievements, including the authorization by the U.S. Food and Drug Administration to commence human clinical trials of its prophylactic breast cancer vaccine, as well as anticipated milestones in its Covid-19 and CAR-T based ovarian cancer therapeutic programs.

Details of Anixa’s presentation are as follows:

Event: H.C. Wainwright BioConnect 2021 Conference

Date & Time: On demand, beginning 6:00 a.m. ET, Monday, January 11, 2021

Webcast link: View Source

An archive of the webcast will remain available for 90 days after the event.